Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 5, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Glioblastoma
Interventions
DRUG

Activated T lymphocyte(Immuncell-LC)

"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"

Trial Locations (7)

Unknown

Hanyang University Guri Hospital, Guri-si

Gyunghee University Medical Center, Seoul

Konkuk University, Seoul

Korea University Anam Hospital, Seoul

Samsung Seoul Medical Center, Seoul

Seoul Asan Medical Center, Seoul

Yeonsei University Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY